Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 0.00 0.00%
S&P 500 1,878.61 3.22 0.17%
NASDAQ 4,148.34 21.37 0.52%
Ticker Volume Price Price Delta
STOXX 50 3,189.81 13.84 0.44%
FTSE 100 6,703.00 28.26 0.42%
DAX 9,548.68 4.49 0.05%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

LifeMap Sciences, a Subsidiary of BioTime, Inc., Announces the Release of MalaCards Version 1.02



  LifeMap Sciences, a Subsidiary of BioTime, Inc., Announces the Release of
  MalaCards Version 1.02

Business Wire

ALAMEDA, Calif. -- January 9, 2013

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX),
announced today the release of MalaCards version 1.02 on January 7. The new
release is available at www.malacards.org. MalaCards is a new database of
human diseases and their annotations that is modeled on the architecture and
richness of the popular GeneCards^® database of human genes. LifeMap Sciences
holds the exclusive worldwide license to market MalaCards and GeneCards^® from
Yeda Research and Development Company Ltd., the commercial arm of the Weizmann
Institute of Science. MalaCards contains computerized “cards” classifying
information relating to a wide array of human diseases. This novel research
tool will aid researchers in studying the roles of genes and cells in disease
processes. MalaCards and GeneCards^® were developed, and are continuously
enhanced by ongoing research, by the bioinformatics team at the Department of
Molecular Genetics at the Weizmann Institute of Science in Israel, with
Professor Doron Lancet, head of the Crown Human Genome Center, and team leader
Marilyn Safran.

The recent release includes enhanced ontology-based accounts of drug-disease
associations, considerably improved portrayal of inter-disease relationships,
including graphical representation of disease networks, MalaCards-unique
disease summaries and the augmentation of anatomical context and related
stem-cell-based therapeutic approaches.

“This new release further underlines how enhanced data resource integration
can lead to a considerably improved research tool,” said Professor Doron
Lancet, Ph.D., head of the Crown Human Genome Center at the Weizmann Institute
of Science.

“MalaCards version 1.02 offers significant improvements for our academic and
commercial users,” stated Yaron Guan-Golan, LifeMap Sciences’ Head of
Marketing. “The introduction of industry standard identifiers like ICD9 and
MeSh will significantly improve enterprise integration and data mining
capabilities. Coupled with our new data sources, including LifeMap Sciences'
own LifeMap Discovery™, we believe that MalaCards is becoming an essential
companion for disease researchers worldwide.”

About LifeMap Sciences, Inc.

LifeMap Sciences’ (www.lifemapsc.com) core technology and business is based on
its integrated database suite, the discovery platform for biomedical and
stem-cell research. This platform includes GeneCards^®, the leading human gene
database; LifeMap Discovery™, the database of embryonic development, stem cell
research and regenerative medicine; and MalaCards, the human disease database.
LifeMap Sciences also markets PanDaTox, an innovative, recently developed,
searchable database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products.

In addition to database offerings, LifeMap Sciences is BioTime’s principal
marketing subsidiary for research products, including PureStem™ human
progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan™
growth media for progenitor cell lines, and cell differentiation media for
non-therapeutic uses, via its LifeMap BioReagents™ portal. LifeMap Sciences
utilizes its databases as part of its online marketing strategy to reach life
sciences researchers at biotech and pharmaceutical companies and at academic
institutions and research hospitals worldwide.

In a therapeutic discovery collaboration with BioTime, LifeMap’s scientists
utilize LifeMap’s proprietary platform, including LifeMap Discovery™, its stem
cell database along with the GeneCards^® and MalaCards integrated database
suite, to aid in the development of BioTime’s proprietary PureStem™ human
progenitor cell lines into products for the treatment of human diseases,
especially degenerative diseases that might be treatable with cell replacement
therapies. The LifeMap Discovery™ platform will be used to select the
progenitor cell lines that are most likely to be useful in developing
cell-based regenerative medicine therapies for a wide range of diseases.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its broad
platform of stem cell technologies is enhanced through subsidiaries focused on
specific fields of application. BioTime develops and markets research products
in the fields of stem cells and regenerative medicine, including a wide array
of proprietary PureStem™ cell lines, HyStem^® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem^®-Rx), a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc. markets GeneCards^®, the leading human gene database, and is developing
an integrated database suite to complement GeneCards^® that will also include
the LifeMap Discovery™ database of embryonic development, stem cell research
and regenerative medicine, and MalaCards, the human disease database. LifeMap
will also market BioTime research products. BioTime Acquisition Corporation
(“BAC”) is a subsidiary being used to acquire the stem cell assets of Geron
Corporation, including patents and other intellectual property, biological
materials, reagents and equipment. BioTime's lead product, Hextend^®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be found on the
web at www.biotimeinc.com.

About the Weizmann Institute of Science and GeneCards

The Weizmann Institute of Science in Rehovot, Israel, is one of the world's
top-ranking multidisciplinary research institutions. Noted for its
wide-ranging exploration of the natural and exact sciences, the Institute is
home to 2,700 scientists, postdoctoral fellows, Ph.D. and M.Sc. students, and
scientific, technical and administrative staff. In addition, visiting
scientists and their families – over 500 from 35 countries in 2010, are
regularly hosted at the Institute. The Institute was founded in 1934 following
a donation to Dr. Chaim Weizmann, a noted biochemist and biotechnologist, who
envisioned the establishment of a world-class scientific research center in
Israel, and later also became the first President of the State of Israel.
Weizmann Institute’s Feinberg Graduate School was established in 1958, where
about 1000 M.Sc. and Ph.D. students are enrolled in studies covering the
Institute’s 18 departments, which are grouped into five faculties:
Biochemistry, Biology, Chemistry, Physics, and Mathematics and Computer
Science. The Institute’s commercial arm, Yeda Research and Development Co. was
the first company of its kind in Israel, and is currently one of the most
successful worldwide. Institute research efforts include the search for new
ways of fighting disease and hunger, examining leading questions in
mathematics and computer science, probing the physics of matter and the
universe, creating novel materials and developing new strategies for
protecting the environment. Particular excellence in bioinformatics and
systems biology is manifested, among others, in the GeneCards project,
initiated in 1996, under the leadership of Prof. Doron Lancet of the Dept. of
Molecular Genetics, Head of the Crown Human Genome Center. A team of 10 led by
Marilyn Safran continuously innovates and keeps GeneCards as a world-top human
gene compendium, automatically mining and integrating 100 world-wide web
resources.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the business of BioTime and its subsidiaries, particularly those
mentioned in the cautionary statements found in BioTime's Securities and
Exchange Commission filings. BioTime disclaims any intent or obligation to
update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:
http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts

Contact:

BioTime, Inc.
Peter Garcia, 510-521-3390, ext. 367
Chief Financial Officer
pgarcia@biotimemail.com
Judith Segall, 510-521-3390, ext. 301
jsegall@biotimemail.com
or
LifeMap Sciences, Inc.
Kenneth Elsner, 781-826-7719
COO
ke@lifemapsc.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement